Israel Englander Glycomimetics Inc Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Glycomimetics Inc stock. As of the latest transaction made, Millennium Management LLC holds 18,865 shares of GLYC stock, worth $5,848. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,865

Previous 186,227 89.87%

Holding current value

$5,848

Previous $52,000 94.23%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.16 - $0.32 $26,777 - $53,555	-167,362 Reduced 89.87%	18,865 $3,000
Q2 2024 Aug 14, 2024	SELL	$0.24 - $3.04 $134,574 - $1.7 Million	-560,727 Reduced 75.07%	186,227 $52,000
Q1 2024 May 15, 2024	BUY	$2.55 - $3.49 $1.81 Million - $2.47 Million	708,066 Added 1820.78%	746,954 $2.24 Million
Q4 2023 Feb 14, 2024	SELL	$1.13 - $2.54 $43,969 - $98,833	-38,911 Reduced 50.01%	38,888 $91,000
Q2 2023 Aug 14, 2023	SELL	$1.21 - $2.08 $498,512 - $856,947	-411,994 Reduced 84.12%	77,799 $135,000
Q1 2023 May 15, 2023	SELL	$1.25 - $4.05 $541,325 - $1.75 Million	-433,060 Reduced 46.93%	489,793 $617,000
Q4 2022 Feb 14, 2023	BUY	$0.57 - $3.03 $317,262 - $1.69 Million	556,601 Added 151.97%	922,853 $2.8 Million
Q3 2022 Nov 14, 2022	SELL	$0.55 - $0.9 $37,621 - $61,562	-68,403 Reduced 15.74%	366,252 $202,000
Q2 2022 Aug 15, 2022	BUY	$0.54 - $1.15 $16,451 - $35,035	30,466 Added 7.54%	434,655 $260,000
Q1 2022 May 16, 2022	SELL	$1.0 - $1.58 $287,524 - $454,287	-287,524 Reduced 41.57%	404,189 $461,000
Q4 2021 Feb 14, 2022	BUY	$1.44 - $2.14 $350,932 - $521,524	243,703 Added 54.4%	691,713 $996,000
Q3 2021 Nov 15, 2021	SELL	$1.8 - $2.39 $429,420 - $570,175	-238,567 Reduced 34.75%	448,010 $981,000
Q2 2021 Aug 16, 2021	BUY	$2.16 - $3.18 $1.38 Million - $2.03 Million	636,986 Added 1284.48%	686,577 $1.59 Million
Q1 2021 May 17, 2021	SELL	$2.89 - $4.22 $499,799 - $729,811	-172,941 Reduced 77.72%	49,591 $149,000
Q4 2020 Feb 16, 2021	BUY	$2.69 - $4.24 $598,611 - $943,535	222,532 New	222,532 $837,000
Q3 2020 Nov 16, 2020	SELL	$3.07 - $5.0 $404,632 - $659,010	-131,802 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$2.06 - $3.76 $53,514 - $97,677	25,978 Added 24.55%	131,802 $496,000
Q1 2020 May 14, 2020	BUY	$1.83 - $5.41 $50,577 - $149,521	27,638 Added 35.35%	105,824 $241,000
Q4 2019 Feb 14, 2020	SELL	$4.03 - $6.5 $617,549 - $996,047	-153,238 Reduced 66.22%	78,186 $414,000
Q3 2019 Nov 14, 2019	BUY	$2.8 - $12.85 $553,991 - $2.54 Million	197,854 Added 589.38%	231,424 $997,000
Q2 2019 Aug 15, 2019	BUY	$10.6 - $13.12 $189,803 - $234,926	17,906 Added 114.31%	33,570 $400,000
Q2 2019 Aug 14, 2019	SELL	$10.6 - $13.12 $27,538 - $34,085	-2,598 Reduced 14.23%	15,664 $374,000
Q1 2019 May 14, 2019	SELL	$9.96 - $13.44 $51,483 - $69,471	-5,169 Reduced 22.06%	18,262 $228,000
Q4 2018 Feb 14, 2019	BUY	$8.47 - $14.71 $198,460 - $344,670	23,431 New	23,431 $222,000
Q3 2018 Nov 14, 2018	SELL	$13.7 - $17.12 $1.8 Million - $2.25 Million	-131,231 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$14.63 - $19.19 $1.54 Million - $2.02 Million	-105,403 Reduced 44.54%	131,231 $2.12 Million
Q1 2018 May 15, 2018	BUY	$16.06 - $25.35 $3.59 Million - $5.66 Million	223,461 Added 1696.36%	236,634 $3.84 Million
Q4 2017 Feb 14, 2018	SELL	$10.51 - $17.22 $7.06 Million - $11.6 Million	-671,832 Reduced 98.08%	13,173 $221,000
Q3 2017 Nov 14, 2017	BUY	$10.14 - $14.85 $6.95 Million - $10.2 Million	685,005	685,005 $9.58 Million

Others Institutions Holding GLYC

# of Institutions

Shares Held

17.8M

Call Options Held

Put Options Held

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.3M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account